"Colitis, Ulcerative" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Descriptor ID |
D003093
|
| MeSH Number(s) |
C06.405.205.265.231 C06.405.205.731.249 C06.405.469.158.188.231 C06.405.469.432.249
|
| Concept/Terms |
Colitis, Ulcerative- Colitis, Ulcerative
- Idiopathic Proctocolitis
- Ulcerative Colitis
- Colitis Gravis
- Inflammatory Bowel Disease, Ulcerative Colitis Type
|
Below are MeSH descriptors whose meaning is more general than "Colitis, Ulcerative".
Below are MeSH descriptors whose meaning is more specific than "Colitis, Ulcerative".
This graph shows the total number of publications written about "Colitis, Ulcerative" by people in this website by year, and whether "Colitis, Ulcerative" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 8 | 0 | 8 |
| 1996 | 5 | 3 | 8 |
| 1997 | 3 | 0 | 3 |
| 1998 | 7 | 2 | 9 |
| 1999 | 4 | 2 | 6 |
| 2000 | 6 | 0 | 6 |
| 2001 | 8 | 2 | 10 |
| 2002 | 6 | 1 | 7 |
| 2003 | 11 | 1 | 12 |
| 2004 | 12 | 0 | 12 |
| 2005 | 6 | 4 | 10 |
| 2006 | 15 | 1 | 16 |
| 2007 | 12 | 4 | 16 |
| 2008 | 11 | 2 | 13 |
| 2009 | 10 | 3 | 13 |
| 2010 | 9 | 0 | 9 |
| 2011 | 22 | 3 | 25 |
| 2012 | 11 | 1 | 12 |
| 2013 | 13 | 2 | 15 |
| 2014 | 8 | 0 | 8 |
| 2015 | 7 | 4 | 11 |
| 2016 | 21 | 5 | 26 |
| 2017 | 17 | 4 | 21 |
| 2018 | 13 | 1 | 14 |
| 2019 | 19 | 4 | 23 |
| 2020 | 23 | 2 | 25 |
| 2021 | 25 | 1 | 26 |
| 2022 | 28 | 0 | 28 |
| 2023 | 22 | 0 | 22 |
| 2024 | 20 | 5 | 25 |
| 2025 | 10 | 1 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Colitis, Ulcerative" by people in Profiles.
-
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
-
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. J Crohns Colitis. 2025 Mar 05; 19(3).
-
Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Rev Clin Immunol. 2025 Apr; 21(4):461-472.
-
Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. Nat Commun. 2025 Jan 21; 16(1):904.
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 Mar; 10(3):210-221.
-
Extensive Disease and Exposure to Multiple Biologics Precolectomy Is Associated with Endoscopic Cuffitis Post-Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2025 01 06; 31(1):72-76.
-
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium. Inflamm Bowel Dis. 2025 01 06; 31(1):131-139.